Viatris
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 5 disclosed transactions, Viatris concentrates its licensing activity in Cardiovascular, Ophthalmology. Viatris pays a 0.70x discount to market median. Their most common deal structure is License, with an average disclosed value of $600M. Most recent activity: 2024.
Pipeline coverage & gaps
Viatris has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 3 | $188M | $633M |
| Collaboration | 1 | $350M | $350M |
| Acquisition | 1 | $750M | $750M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2024 | Sotagliflozin (Inpefa) | Lexicon Pharmaceuticals | HF (HFrEF and HFpEF) | approved | $185M | $500M |
| 2024 | Aprocitentan (Tryvio) | Idorsia | heart_failure | approved | $350M | $1.0B |
| 2023 | myopiaProgression | Ocuphire Pharma | myopiaProgression | phase_3 | $30M | $400M |
| 2023 | thrombosis | Idorsia | thrombosis | phase_3 | $350M | $350M |
| 2022 | Tyrvaya (varenicline nasal spray) | Oyster Point Pharma | Dry Eye Disease | approved | $750M | $750M |
How this is computed
For each Viatris deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.501, clamped to [0.7, 1.5].